Avan J. Armaghani, MD, provides a postconference perspective on data shared at ASCO 2022. The cumulative effect of the latest results from the DESTINY-Breast04 study are, in Dr Armaghani's view, "practice-changing," and perhaps most importantly by the consolidation of a new clinical category, HER2-low, which represents a more nuanced picture in the treatment of metastatic breast cancer. In the revised scheme, a subgroup of patients previously considered as HER2-negative are now redefined as an autonomous population, with an accompanying distinction in therapeutic approach.
This new formulation, together with parallel benefits Dr Armaghani describes in the triple-negative setting, amount to "a new era in how we treat breast cancer."
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: A New Era in the Treatment of Metastatic Breast Cancer - Medscape - Jun 22, 2022.